Current ATM View - PSC002321
EOI Process Equipment for the new ANSTO Nuclear Medicine Manufacturing Facility and associated infrastructure
Sydney
ANSTO is a corporate Commonwealth entity and Australia’s nuclear research and technology organisation. ANSTO is responsible for delivering specialised advice, scientific services and products to government, industry, academia and other research organisations. One of ANSTO's core missions, as the centre of Australian nuclear expertise, is to manufacture and advance the use of radiopharmaceuticals which will improve the health of Australians. This is undertaken by the ANSTO Health division.
ANSTO and the Australian Government are working to secure the long-term supply of nuclear medicines for Australia. ANSTO’s building 23 facility is coming to the end of its operational life and has been deemed by regulators and independent experts to be in need of replacement. On 9 May 2023, the Government announced as part of its financial year 2023/24 budget that it would, “support the resilience of nuclear medicine supply chains through the design and construction of a new, safe and reliable nuclear medicine manufacturing facility and sustainment of existing capabilities.” This new facility will be located at the ANSTO site Lucas Heights, NSW.
To give effect to this support, “The Government will provide funding over 10 years from 2023–24 to support the Australian Nuclear Science and Technology Organisation (ANSTO) in its provision of nuclear medicines to Australians, including full funding to construct a new nuclear medicine manufacturing building, as well as ongoing maintenance of the current ageing facility”.
The general purpose of the Requirement is to design, manufacture, supply, install and commissioning the product manufacturing process equipment for the Program. The replacement facility will need to manufacture three ‘core’ products in sufficient quantities to meet demand. This section identifies the products and volumes before specifying the infrastructure required.
The core product requirements are described below:
a) Technetium: Production of between 200 and 400 generators per week;
b) Lutetium: Production capacity of 20TBq per week; and
c) Iodine: Production capacity of 25TBq per week.
Suppliers must:
1. sign and return the Confidentiality Undertaking to ANSTO;
2. provide a Response in respect of at least one (1) EOI Package; and
3. sign and return the Deed of Undertaking to ANSTO, including an acknowledgment that signing the final form of Pre-Engineering Terms issued by ANSTO is a mandatory requirement to be shortlisted for and participate in Pre-Engineering and the RFT for a Shortlisted Package.
4. demonstrate delivery of two projects in the last ten (10) years cells for the production of Technetium-99m, Lutetium-177 or Iodine-131 nuclear medicine Active Pharmaceutical Ingredient (API), or an equivalent product or radioisotope, excluding cyclotron produced isotopes. One or more of the selected projects shall be inclusive of both the containment structures and process manufacturing equipment. One or more of the selected projects shall have a total outturn cost of >$10M.
5. a Tenderer may not submit a Response for an EOI Package and at the same time participate, in any capacity (whether through an associated vehicle or otherwise), with another Supplier for the same EOI Package.
Refer to EOI documentation.